Medicus Pharma marks Nasdaq anniversary with opening bell ceremony

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company was honored with the opportunity to ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York’s Times Square, marking the one-year anniversary of Medicus’ listing on the Nasdaq exchange.

Dr. Bokhari said the milestone reflects the company’s progress since going public and highlights its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio. Since its Nasdaq debut, Medicus has concentrated on advancing key therapeutic assets through Phase 2 proof-of-concept studies while actively pursuing licensing opportunities and strategic partnerships with established pharmaceutical companies that are well positioned to manage late-stage development and global commercialization.

Medicus’ current development pipeline is anchored by two lead programs. SkinJect is a localized, immunogenic precision therapy being developed for the treatment of basal cell carcinoma, the most common form of skin cancer. The company estimates SkinJect addresses a market opportunity of approximately $2 billion.

The pipeline also includes Teverelix, a next-generation gonadotropin-releasing hormone (GnRH) antagonist designed for patients with advanced prostate cancer who are at high cardiovascular risk and susceptible to acute urinary retention relapse. Medicus estimates the combined market opportunity for its pipeline assets at approximately $6 billion. The company announced today that the royalty rate payable on worldwide net sales of Teverelix has been reduced from ~4% to 2%, with the royalty term clarified on a country-by-country basis in line with standard industry practice. The company says this makes Teverelix more attractiveness for future partnering.

#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews #nasdaq #bellringing